NCCN Guidelines for Patients® | Lung Cancer - Non-Small Cell Lung Cancer

56 NCCN Guidelines for Patients ® : Lung Cancer – Non-Small Cell, 2018 5 Overview of cancer treatments Immunotherapy Immunotherapy The immune system is the body’s natural defense against disease. It includes many chemicals and proteins made by your body. Immunotherapy increases the activity of your immune system. Your body can better find and destroy cancer cells. PD-1 and PD-L1 inhibitors PD-L1 is found on some normal cells. It attaches PD-1 on T cells to turn off an immune response. This is a normal when a response is no longer needed. Cancer cells with PD-L1 can also turn off the immune response. This prevents the immune system from attacking the tumor. The PD-L1 and PD-1 inhibitors listed in Guide 7 are used to stop cancer cells with PD-L1. PD-L1 inhibitors attach to PD-1 on T cells. PD-1 inhibitors attach to PD-1 on cancer cells. Both types of inhibitors stop cancer cells with PD-L1 from attaching to T cells. Thus, T cells are able to attack cancer cells. See Figure 20 . Figure 20 Immunotherapy Some lung cancers consist of cells that have PD-L1 on their surface. PD-L1 can attach to T cells and stop them from attacking cancer cells. Immunotherapy for lung cancer stops PD-L1 from attaching. As a result, T cells are able to attack cancer cells. Copyright © 2017 National Comprehensive Cancer Network ® (NCCN ® ). Guide 7. Immunotherapy Generic (chemical) name Brand name (sold as) Type Atezolizumab Tecentriq ® PD-L1 inhibitor Durvalumab Imfinzi™ PD-L1 inhibitor Nivolumab Opdivo ® PD-1 inhibitor Pembrolizumab Keytruda ® PD-1 inhibitor T cell PD-L1 PD-1 nivolumab pembrolizumab cancer cell atezolizumab durvalumab